- Home
- AYTU vs RDHL Comparison
AYTU vs RDHL Comparison
Compare AYTU & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- RDHL
- Stock Information
- Founded
- AYTU N/A
- RDHL 2009
- Country
- AYTU United States
- RDHL Israel
- Employees
- AYTU N/A
- RDHL N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- AYTU Health Care
- RDHL Health Care
- Exchange
- AYTU Nasdaq
- RDHL Nasdaq
- Market Cap
- AYTU 23.0M
- RDHL 3.9M
- IPO Year
- AYTU N/A
- RDHL N/A
- Fundamental
- Price
- AYTU $2.15
- RDHL $1.16
- Analyst Decision
- AYTU Strong Buy
- RDHL
- Analyst Count
- AYTU 3
- RDHL 0
- Target Price
- AYTU $9.17
- RDHL N/A
- AVG Volume (30 Days)
- AYTU 92.6K
- RDHL 2.8M
- Earning Date
- AYTU 11-13-2025
- RDHL 09-05-2025
- Dividend Yield
- AYTU N/A
- RDHL N/A
- EPS Growth
- AYTU N/A
- RDHL N/A
- EPS
- AYTU N/A
- RDHL N/A
- Revenue
- AYTU $66,382,000.00
- RDHL $9,550,000.00
- Revenue This Year
- AYTU N/A
- RDHL $381.91
- Revenue Next Year
- AYTU $29.12
- RDHL N/A
- P/E Ratio
- AYTU N/A
- RDHL N/A
- Revenue Growth
- AYTU 1.84
- RDHL 157.62
- 52 Week Low
- AYTU $0.95
- RDHL $1.04
- 52 Week High
- AYTU $2.82
- RDHL $8.75
- Technical
- Relative Strength Index (RSI)
- AYTU 44.77
- RDHL 33.72
- Support Level
- AYTU $2.10
- RDHL $1.64
- Resistance Level
- AYTU $2.31
- RDHL $1.60
- Average True Range (ATR)
- AYTU 0.14
- RDHL 0.21
- MACD
- AYTU -0.02
- RDHL -0.06
- Stochastic Oscillator
- AYTU 56.45
- RDHL 11.19
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.